311 related articles for article (PubMed ID: 3568456)
1. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.
Baltz ML; Caspi D; Evans DJ; Rowe IF; Hind CR; Pepys MB
Clin Exp Immunol; 1986 Dec; 66(3):691-700. PubMed ID: 3568456
[TBL] [Abstract][Full Text] [Related]
2. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
Maeda S
Amyloid; 2003 Aug; 10 Suppl 1():17-20. PubMed ID: 14640037
[TBL] [Abstract][Full Text] [Related]
3. Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains.
Baltz ML; Gomer K; Davies AJ; Evans DJ; Klaus GG; Pepys MB
Clin Exp Immunol; 1980 Feb; 39(2):355-60. PubMed ID: 7389204
[TBL] [Abstract][Full Text] [Related]
4. Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy.
Murakami T; Yi S; Maeda S; Tashiro F; Yamamura K; Takahashi K; Shimada K; Araki S
Am J Pathol; 1992 Aug; 141(2):451-6. PubMed ID: 1497094
[TBL] [Abstract][Full Text] [Related]
5. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
6. Increased serum amyloid a levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice.
de Villiers WJ; Varilek GW; de Beer FC; Guo JT; Kindy MS
Cytokine; 2000 Sep; 12(9):1337-47. PubMed ID: 10975993
[TBL] [Abstract][Full Text] [Related]
7. Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition.
Snel FW; Niewold TA; Baltz ML; Hol PR; Van Ederen AM; Pepys MB; Gruys E
Clin Exp Immunol; 1989 May; 76(2):296-300. PubMed ID: 2474395
[TBL] [Abstract][Full Text] [Related]
8. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component.
Hawkins PN; Myers MJ; Epenetos AA; Caspi D; Pepys MB
J Exp Med; 1988 Mar; 167(3):903-13. PubMed ID: 3351437
[TBL] [Abstract][Full Text] [Related]
9. Plasma kinetics of 125I-labelled amyloid P component in beta 2M amyloidosis: a possible approach to quantitate disease activity.
Zingraff J; Caillat-Vigneron N; Ureña P; Gagné ER; Bererhi L; Moretti JL; Bardin T; Drüeke TB
Nephrol Dial Transplant; 1995; 10(2):223-9. PubMed ID: 7753457
[TBL] [Abstract][Full Text] [Related]
10. Rapid induction of experimental AA amyloidosis in mink by intravenous injection of amyloid enhancing factor.
Sørby R; Espenes A; Landsverk T; Westermark G
Amyloid; 2008 Mar; 15(1):20-8. PubMed ID: 18266118
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Pepys MB
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
[TBL] [Abstract][Full Text] [Related]
12. Formation of experimental murine AA amyloid fibrils in SAP-deficient mice: high resolution ultrastructural study.
Inoue S; Kawano H; Ishihara T; Maeda S; Ohno S
Amyloid; 2005 Sep; 12(3):157-63. PubMed ID: 16194870
[TBL] [Abstract][Full Text] [Related]
13. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.
Hutchinson WL; Noble GE; Hawkins PN; Pepys MB
J Clin Invest; 1994 Oct; 94(4):1390-6. PubMed ID: 7929814
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical identification of amyloid, using an anti-human serum amyloid P component (SAP) antibody, is possible in ruminants but not in dogs and cats.
Hartig W; Leifsson PS; Nielsen OL
J Vet Med A Physiol Pathol Clin Med; 2005 Nov; 52(9):447-53. PubMed ID: 16268955
[TBL] [Abstract][Full Text] [Related]
15. Amyloid P-component in mice injected with casein: identification in amyloid deposits and in the cytoplasm of hepatocytes.
Baltz ML; Dyck RF; Pepys MB
Immunology; 1980 Sep; 41(1):59-66. PubMed ID: 7000694
[TBL] [Abstract][Full Text] [Related]
16. Brefeldin A inhibits experimentally induced AA amyloidosis.
Stenstad T; Husby G
J Rheumatol; 1996 Jan; 23(1):93-100. PubMed ID: 8838515
[TBL] [Abstract][Full Text] [Related]
17. Amyloid enhancing factor is produced by rats and amyloid-resistant CE/J mice.
Gonnerman WA; Kandel R; Cathcart ES
Lab Invest; 1996 Jan; 74(1):259-64. PubMed ID: 8569190
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of amyloid A (AA) protein and amyloid P component (AP) in deposits of systemic amyloidosis associated with renal adenocarcinoma.
Hind CR; Tennent GA; Evans DJ; Pepys MB
J Pathol; 1983 Feb; 139(2):159-66. PubMed ID: 6338184
[TBL] [Abstract][Full Text] [Related]
19. Homozygous serum amyloid P component-deficiency does not enhance regression of AA amyloid deposits.
Usui I; Kawano H; Ito S; Hamada Y; Ishihara T; Maeda S
Amyloid; 2001 Jun; 8(2):101-4. PubMed ID: 11409030
[TBL] [Abstract][Full Text] [Related]
20. Diffusible amyloid oligomers trigger systemic amyloidosis in mice.
Senthilkumar S; Chang E; Jayakumar R
Biochem J; 2008 Oct; 415(2):207-15. PubMed ID: 18564059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
